| 1 |
NCT02728414 |
Recruiting |
Probiotics Effect on Glucose and Lipid Metabolism and Gut Microbiota in Patients With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Dietary Supplement: probiotics
- Dietary Supplement: placebo
|
Interventional |
Not Applicable |
- Shanghai 10th People's Hospital
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- change from baseline in fasting blood-glucose at 1 month
- change from baseline in fasting blood-glucose at 3 months
- change from baseline in glycosylated hemoglobin change at 1 month
- (and 33 more...)
|
100 |
All |
20 Years to 80 Years (Adult, Senior) |
NCT02728414 |
PTD01 |
|
October 2015 |
December 2017 |
December 2017 |
April 5, 2016 |
March 10, 2017 |
|
- Shanghai 10th People's Hospital
Shanghai, Shanghai, China
|
| 2 |
NCT01213563 |
Completed |
Management of Type 2 Diabetes After Gastric Bypass Surgery |
- Diabetes Mellitus, Type 2
|
- Drug: Actrapid insulin+Gloucose
- Drug: Actrapid insulin
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Participant)
- Primary Purpose: Supportive Care
|
- efficacy and safety of an intensive glycaemic protocol after bariatric surgery
|
50 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01213563 |
09/808 |
|
January 2009 |
September 2010 |
September 2010 |
October 4, 2010 |
August 11, 2017 |
|
- Imperial College London, Charing Cross Hospital
London, United Kingdom
|
| 3 |
NCT03160196 |
Not yet recruiting |
Efficacy of an Electronic System to Support Clinical Decisions in Adults With Type 2 Diabetes Mellitus. |
- Diabetes Mellitus, Type 2
|
- Other: Clinical Decision Support System
- Other: Usual care based on clinical practice guideline
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- Proportions of participants with normal Hb1Ac
|
1768 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT03160196 |
|
OSI-DM |
January 2018 |
September 2019 |
September 2019 |
May 19, 2017 |
May 19, 2017 |
|
|
| 4 |
NCT02689362 |
Recruiting |
Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2) |
- Diabetes Mellitus, Type 2
|
- Drug: Evogliptin
- Drug: Sitagliptin
- Drug: Placebo Evogliptin
- Drug: Placebo Sitagliptin
|
Interventional |
Phase 2 |
- Eurofarma Laboratorios S.A.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Absolute variation of the values obtained in the baseline for the HbA1c
- Absolute variation of the values obtained in the baseline for the parameter, fasting blood glucose.
- Absolute variation of the values obtained in the baseline for the parameter, body weight.
|
144 |
All |
20 Years to 75 Years (Adult, Senior) |
NCT02689362 |
EF144 |
EVOLUTION |
August 8, 2017 |
December 2018 |
December 2018 |
February 23, 2016 |
March 26, 2018 |
|
- Centro de Estudos em Diabetes e Hipertensão
Fortaleza, Ceará, Brazil - Hospital Universitário João de Barros Barreto - HUJBB
Belém, Pará, Brazil - CCBR Brasil Centro de Pesquisas e Analises Clinicas Ltda
Rio de Janeiro, Brazil - (and 7 more...)
|
| 5 |
NCT00871572 |
Completed |
A Study for Patients With Type 2 Diabetes Mellitus |
- Diabetes Mellitus, Type 2
|
- Drug: LY2409021
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean change in hemoglobin A1c
- Change from baseline values for fasting glucose
- Change from baseline for glucose area under the curve from Oral Glucose Tolerance Test
- (and 13 more...)
|
87 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00871572 |
11095
I1R-MC-GLBE |
|
March 2009 |
February 2010 |
February 2010 |
March 30, 2009 |
December 15, 2010 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Buena Park, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Huntington Park, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Westlake Village, California, United States - (and 16 more...)
|
| 6 |
NCT03199053 |
Recruiting |
Study to Evaluate Safety and Efficacy of Dapagliflozin and Saxagliptin in Patients With Type 2 Diabetes Mellitus Aged 10 to Below 18 Years Old |
- Diabetes Mellitus, Type 2
|
- Drug: Dapagliflozin
- Drug: Saxagliptin
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline in HbA1c at Week 26
- Change from baseline in Fasting Plasma Glucose at Week 26
- Percentage of subjects with baseline HbA1c ≥ 7%, who achieve an HbA1c level < 7.0% at Week 26
|
243 |
All |
10 Years to 18 Years (Child, Adult) |
NCT03199053 |
D1680C00019
2015-005042-66 |
|
October 11, 2017 |
October 21, 2020 |
September 22, 2021 |
June 26, 2017 |
March 30, 2018 |
|
- Research Site
Saraland, Alabama, United States - Research Site
Sacramento, California, United States - Research Site
Washington, District of Columbia, United States - (and 152 more...)
|
| 7 |
NCT03196895 |
Recruiting |
Treating Type 2 Diabetes by Reducing Postprandial Glucose Elevations: A Paradigm Shift in Lifestyle Modification |
- Diabetes Mellitus, Type 2
|
- Behavioral: Weight reduction training
- Behavioral: PPG training
- Behavioral: discrete BG feedback
- Behavioral: continuous BG feedback
|
Interventional |
Not Applicable |
- University of Virginia
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- change in HbA1c
- change in medication
- change in food choices (ASA24 survey)
- (and 10 more...)
|
200 |
All |
21 Years to 80 Years (Adult, Senior) |
NCT03196895 |
19370
1R01DK108957 |
|
June 28, 2017 |
June 2021 |
August 2021 |
June 23, 2017 |
October 26, 2017 |
|
- Dept. of Psychiatry and Neurobehavioral Sciences, University of Virginia
Charlottesville, Virginia, United States
|
| 8 |
NCT02843724 |
Not yet recruiting |
Integrative Care for Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Other: Naturopathic Care
- Other: Usual (Conventional) Care
|
Interventional |
Phase 1
Phase 2 |
- The Canadian College of Naturopathic Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Clinically meaningful reduction of HbA1c above and beyond that of control arm
- Incidence of metabolic syndrome
- Weight (as part of BMI)
- (and 20 more...)
|
148 |
All |
21 Years to 75 Years (Adult, Senior) |
NCT02843724 |
CanadianCNN |
|
July 2016 |
December 2018 |
July 2019 |
July 26, 2016 |
July 26, 2016 |
|
- Wise Elephant Family Health Team
Brampton, Ontario, Canada - The Canadian College of Naturopathic Medicine
Toronto, Ontario, Canada
|
| 9 |
NCT01578096 |
Completed |
Stress Management Among Latinos With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Behavioral: stress management
|
Interventional |
Not Applicable |
- Yale University
- Hartford Hospital
- UConn Health
- Hispanic Health Council
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hemoglobin A1c
- Diabetes specific distress
|
107 |
All |
18 Years and older (Adult, Senior) |
NCT01578096 |
R01MD005879 |
CALMS-D |
May 2012 |
December 2014 |
June 2015 |
April 16, 2012 |
August 21, 2015 |
|
- Yale University
New Haven, Connecticut, United States
|
| 10 |
NCT03314246 |
Recruiting |
Development and Implementation of Ramadan Fasting Algorithm for Singaporeans With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Other: FAST
- Other: Standard of care
|
Interventional |
Not Applicable |
- Joyce Lee
- National University, Singapore
- Tan Tock Seng Hospital
- National Healthcare Group, Singapore
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Change in HbA1c
- Incidence of minor and major hypoglycemia
- Incidence of hyperglycemia
- (and 8 more...)
|
400 |
All |
21 Years to 90 Years (Adult, Senior) |
NCT03314246 |
2016/00290 |
FAST |
April 3, 2017 |
December 2018 |
December 2018 |
October 19, 2017 |
October 19, 2017 |
|
- Tan Tock Seng Hospital
Singapore, Singapore - National Healthcare Group Polyclinic (Bukit Batok)
Singapore, Singapore
|
| 11 |
NCT01498367 |
Completed |
Life-long Tele-monitoring of Patients With Type 2 Diabetes Mellitus in Central Greece |
- Diabetes Mellitus, Type 2
|
- Procedure: Telemonitoring of patients with diabetes type 2
|
Interventional |
Not Applicable |
- Regional Health Authority of Sterea & Thessaly
- Ministry for Health and Social Solidarity, Greece
- Municipality of Trikala, Greece
- (and 7 more...)
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Health related quality of life of the patients measured by the SF-36 version 2 questionnaire
- HbA1c levels
- Emotional functioning in diabetes assessed by the "Problem areas in diabetes questionnaire - PAID © 1999 Joslin Diabetes Center"
- (and 4 more...)
|
154 |
All |
18 Years and older (Adult, Senior) |
NCT01498367 |
FR2015
EC Grant Agreement 250487 |
RHCluster2GR |
March 2011 |
December 2013 |
January 2014 |
December 23, 2011 |
February 18, 2015 |
|
- Endocrinology and Metabolic Diseases Department - Regional University Hospital of Larisa
Larisa, Thessaly, Greece
|
| 12 |
NCT01582243 |
Completed
Has Results |
Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients |
- Diabetes Mellitus, Type 2
|
|
Interventional |
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
- Mean Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
- Mean Change From Baseline in Fasting Plasma Glucose(FPG) at Week 12 and 24
- (and 3 more...)
|
40 |
All |
20 Years and older (Adult, Senior) |
NCT01582243 |
CLAF237ATW03 |
|
April 2013 |
September 2015 |
September 2015 |
April 20, 2012 |
November 3, 2016 |
November 3, 2016 |
- Novartis Investigative Site
Changhua, Taiwan
|
| 13 |
NCT02879383 |
Recruiting |
Effect of DMR Using the Revita System in the Treatment of Type 2 Diabetes (T2D) |
- Diabetes Mellitus, Type 2
- Noninsulin-Dependent Diabetes Mellitus
|
- Procedure: DMR Procedure
- Procedure: Sham Procedure
|
Interventional |
Not Applicable |
- Fractyl Laboratories, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- MMTT plasma glucose DMR vs Sham
- Safety: Incidence rates of device or procedure related SAEs and UADEs
- HbA1c at 24 weeks DMR vs. Sham
- (and 6 more...)
|
110 |
All |
28 Years to 75 Years (Adult, Senior) |
NCT02879383 |
C-30000 |
|
March 1, 2017 |
October 2018 |
April 2019 |
August 25, 2016 |
November 14, 2017 |
|
- Hopital Erasme
Brussels, Belgium - UZ Leuven
Leuven, Belgium - Hospital das Clinicas da Faculdade de medicina da Universidade de São Paulo
Sao Paulo, Brazil - (and 6 more...)
|
| 14 |
NCT01241448 |
Completed |
A Study of LY2409021 in Patients With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Drug: LY2409021
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from baseline to 24 week endpoint in Hemoglobin A1c (HbA1c)
- Change from baseline to 24 week endpoint in fasting blood glucose (FBG)
- Change from baseline to 24 week endpoint in 7-point self monitored glucose (SMBG) profile
- (and 12 more...)
|
260 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01241448 |
13031
I1R-MC-GLBG |
|
January 2011 |
February 2012 |
March 2012 |
November 16, 2010 |
June 1, 2012 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Burbank, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Concord, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fresno, California, United States - (and 37 more...)
|
| 15 |
NCT01030679 |
Completed |
Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes Mellitus |
- Diabetes Mellitus, Type 2
|
- Drug: CKD-501 0.5mg
- Drug: CKD-501 1mg
- Drug: CKD-501 2mg
- Drug: Placebo
|
Interventional |
Phase 2 |
- Chong Kun Dang Pharmaceutical
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in fasting plasma glucose at 8 weeks
- Change from baseline in Glycemic parameters after 8 weeks
- Change from baseline in Lipid parameters after 8 weeks
- Adverse event profile after 8 weeks of treatment
|
214 |
All |
19 Years and older (Adult, Senior) |
NCT01030679 |
19DM05L |
|
July 2007 |
October 2008 |
October 2008 |
December 11, 2009 |
December 16, 2009 |
|
- The Inje University Medical Center
Busan, Korea, Republic of - The Yeungnam University Hospital
Daegu, Korea, Republic of - The Chtholic University of Korea Uijeongbu St. Mary's Hospital
Gyeonggi-do, Korea, Republic of - (and 5 more...)
|
| 16 |
NCT03318913 |
Completed |
Vascular Function, Fish Protein Hydrolysates and Type 2 Diabetes Mellitus |
- Diabetes Mellitus, Type 2
|
- Other: Placebo
- Other: Fish protein hydrolysates
|
Interventional |
Not Applicable |
- Universidade Federal do Rio de Janeiro
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Flow-mediated dilation
- Near infrared spectroscopy
- High performance liquid chromatography
|
22 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT03318913 |
53392216.0.0000.5699 |
|
October 3, 2016 |
February 15, 2017 |
March 15, 2017 |
October 24, 2017 |
October 24, 2017 |
|
|
| 17 |
NCT02252965 |
Completed
Has Results |
Metformin Extended Release Versus Metformin Immediate Release in Subjects With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Drug: Metformin IR
- Drug: Metformin XR
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16
- Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period
- Percentage of Subjects With Pre-specified Gastrointestinal Adverse Events During Treatment Period
- (and 8 more...)
|
532 |
All |
18 Years to 79 Years (Adult, Senior) |
NCT02252965 |
200084-513 |
CONSENT |
December 2014 |
November 2015 |
April 2016 |
September 30, 2014 |
January 24, 2017 |
January 24, 2017 |
- Please contact the Merck KGaA Communication Center
Darmstadt, Germany
|
| 18 |
NCT01421459 |
Completed
Has Results |
A Study in Adults With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Drug: LY2963016
- Drug: Lantus
- Drug: OAMs
|
Interventional |
Phase 3 |
- Eli Lilly and Company
- Boehringer Ingelheim
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline up to 24 Weeks in Hemoglobin A1c (HbA1c)
- Change From Baseline in Insulin Antibody Levels
- Change From Baseline in Hemoglobin A1c (HbA1c)
- (and 10 more...)
|
759 |
All |
18 Years and older (Adult, Senior) |
NCT01421459 |
13713
I4L-MC-ABEC
2011-000828-15 |
ELEMENT 2 |
September 2011 |
September 2012 |
September 2012 |
August 22, 2011 |
December 18, 2014 |
October 9, 2014 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Montgomery, Alabama, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Brooksville, Florida, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fort Lauderdale, Florida, United States - (and 59 more...)
|
| 19 |
NCT02891382 |
Completed |
Feasibility Study on the Impact of Economic Incentives to Improve the Management of Type 2 Diabetes Mellitus |
- Diabetes Mellitus, Type 2
|
- Behavioral: Diabetes education
- Behavioral: Goal setting
- Behavioral: Companion Support
- (and 2 more...)
|
Interventional |
Not Applicable |
- Universidad Peruana Cayetano Heredia
- Johns Hopkins Bloomberg School of Public Health
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Glycated hemoglobin
- Weight loss
|
54 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT02891382 |
MR/M007405/1 |
REDEEM-Pilot |
July 2016 |
February 2017 |
February 2017 |
September 7, 2016 |
January 19, 2018 |
|
- Hospital Nacional Arzobispo Loayza
Lima, Peru
|
| 20 |
NCT01453049 |
Terminated
Has Results |
An Efficacy and Safety Study of Fixed-dose Rosiglitazone/Glimepiride to Treat Chinese Type 2 Diabetes Patients |
- Diabetes Mellitus, Type 2
|
- Drug: rosiglitazone/glimepiride fix dose combination
- Drug: glimepiride
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24
- Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24
- Number of HbA1c Responders and Non-responders
- (and 30 more...)
|
86 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01453049 |
113263 |
|
April 2010 |
October 2010 |
October 2010 |
October 17, 2011 |
March 27, 2012 |
January 13, 2012 |
- GSK Investigational Site
Wuhan, Hubei, China - GSK Investigational Site
Suzhou, Jiangsu, China - GSK Investigational Site
Dalian, Liaoning, China - (and 9 more...)
|
| 21 |
NCT00290927 |
Completed |
Efficacy and Safety of Insulin Glulisine in Type 2 Diabetes Mellitus |
- Diabetes Mellitus, Type 2
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Efficacy: change in HbA1C from baseline to endpoint (superiority of HMR1964 and OHA combination therapy as compared to OHA therapy, superiority of HMR1964 mono-therapy as compared to OHA therapy)
- Safety of HMR1964
- change in HbA1C from baseline to week 16,consecutive change in HbA1C every 4 wks,plasma glucose parameters, symptomatic hypoglycemia (comparison of HMR1964 intensive therapy, mono-or OHA combination therapy, with OHA therapy).
|
390 |
All |
20 Years to 75 Years (Adult, Senior) |
NCT00290927 |
EFC6168 |
|
December 2003 |
|
|
February 13, 2006 |
August 26, 2009 |
|
- Sanofi-Aventis
Tokyo, Japan
|
| 22 |
NCT02688075 |
Completed |
An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada |
- Diabetes Mellitus, Type 2
|
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at 6 and 12 Months
- Change From Baseline in Mean Glycosylated Hemoglobin (HbA1c) at 3, 6 and 12 Months by HbA1c Subgroup
- Percentage of Participants Achieving Glycosylated Hemoglobin (HbA1c) Less Than (<) 7.0 Percent (%)
- (and 9 more...)
|
538 |
All |
18 Years and older (Adult, Senior) |
NCT02688075 |
CR107542
28431754DIA4012 |
CanCARE |
November 13, 2015 |
August 17, 2017 |
August 17, 2017 |
February 23, 2016 |
October 30, 2017 |
|
- Calgary, Alberta, Canada
- Edmonton, Alberta, Canada
- Coquitlam, British Columbia, Canada
- (and 20 more...)
|
| 23 |
NCT00791479 |
Completed
Has Results |
Effects of LY2189265 on Glycemic Control in Participants With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Drug: LY2189265 and Lifestyle Measures
- Drug: Placebo solution and Lifestyle Measures
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in Glycosylated Hemoglobin (HbA1c)
- Change From Baseline in Fasting Blood Glucose
- Percentage of Participants Who Achieve Glycosylated Hemoglobin (HbA1c) <7% or ≤6.5%
- (and 13 more...)
|
167 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00791479 |
12565
H9X-MC-GBCK
CTRI/2009/091/000105 |
|
December 2008 |
January 2010 |
January 2010 |
November 14, 2008 |
December 10, 2014 |
December 10, 2014 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Concord, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Lancaster, California, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Mission Hills, California, United States - (and 43 more...)
|
| 24 |
NCT01931631 |
Suspended |
Plant-Based Dietary Intervention in Type 2 Diabetes-2 |
- Diabetes Mellitus, Type 2
|
- Behavioral: Low-fat, low-Glycemic Index, vegan diet
- Behavioral: ADA diet
|
Interventional |
Not Applicable |
- Physicians Committee for Responsible Medicine
- George Washington University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hemoglobin A1c
- Body Weight
- Blood Pressure
- (and 13 more...)
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT01931631 |
PCRM GWU DM Study-2 |
WCCR-DIAB2 |
January 2014 |
January 2019 |
January 2019 |
August 29, 2013 |
April 10, 2018 |
|
- Physicians Committee for Responsible Medicine
Washington, District of Columbia, United States
|
| 25 |
NCT03416127 |
Not yet recruiting |
Effect of Propolis or Metformin Administration on Glycemic Control in Patients With Diabetes Mellitus Type 2 |
- Diabetes Mellitus, Type 2
|
- Drug: Propolis
- Drug: Metformin
- Drug: Placebo
|
Interventional |
Phase 2 |
- University of Guadalajara
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Changes in fasting glucose levels after 12 weeks of intervention with propolis, metformin and placebo
- Changes in postprandial glucose levels after 12 weeks of intervention with propolis, metformin and placebo
- Changes in glycosylated hemoglobin (A1C) after 12 weeks of intervention with propolis, metformin and placebo
- (and 15 more...)
|
36 |
All |
30 Years to 60 Years (Adult) |
NCT03416127 |
PROPOLIS-METFORMIN-DM2 |
|
March 1, 2018 |
March 1, 2019 |
May 1, 2019 |
January 30, 2018 |
February 2, 2018 |
|
- Intstituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara
Guadalajara, Jalisco, Mexico
|
| 26 |
NCT03473262 |
Active, not recruiting
New |
Empagliflozin-based Quadruple Combination vs Insulin Glarine-based Combination Therapy in Patients With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
|
Observational |
|
- Chungbuk National University Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Changes in HbA1c From Baseline to Week 24
- Changes in Fasting Plasma Glucose From Baseline to Week 24
- Percentage of Patients Who Achieved Glycemic Target of HbA1c ≤7.0% at Week 24
- (and 12 more...)
|
200 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT03473262 |
2017-03-011
eujeongku |
|
January 1, 2017 |
July 1, 2018 |
December 31, 2018 |
March 22, 2018 |
March 22, 2018 |
|
|
| 27 |
NCT03421119 |
Not yet recruiting |
Comparing Efficacy and Safety of CinnaGen-liraglutide Versus Victoza® in Patients With Type II Diabetes |
- Diabetes Mellitus, Type 2
|
- Drug: Liraglutide 6 MG/ML Pen Injector
- Drug: Metformin
- Drug: Sulfonylurea/non-sulfonylurea insulin secretagogues
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- HbA1c
- HbA1c < 7.0%
- HbA1c ≤ 6.5%
- (and 9 more...)
|
300 |
All |
30 Years to 65 Years (Adult) |
NCT03421119 |
LIR.CIN.MK95 |
|
April 30, 2018 |
December 1, 2019 |
December 1, 2019 |
February 2, 2018 |
February 20, 2018 |
|
|
| 28 |
NCT01289119 |
Completed
Has Results |
Efficacy and Safety of Alogliptin in Participants With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Drug: Alogliptin
- Drug: Placebo to alogliptin
- Drug: Metformin
- Drug: Pioglitazone
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Glycosylated Hemoglobin (HbA1c)
- Change From Baseline in HbA1c Over Time
- Change From Baseline in Fasting Plasma Glucose Over Time
- (and 9 more...)
|
506 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01289119 |
SYR-322_02
U1111-1118-3681
SYR-322_308 |
|
December 2010 |
December 2011 |
December 2011 |
February 3, 2011 |
March 22, 2013 |
March 22, 2013 |
- Beijing, Beijing, China
- Fuzhou, Fujian, China
- Xiamen, Fujian, China
- (and 18 more...)
|
| 29 |
NCT02341690 |
Active, not recruiting |
Intervention Study - Effectiveness of Smartphone Delivered Interval Walking Training to Patients With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Other: Interval walking training
- Other: control
|
Interventional |
Not Applicable |
- University of Copenhagen
- Center for Physical Activity Research (CFAS)
- The Danish Center for Strategic Research on Type 2 Diabetes
- (and 2 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Changes in Physical activity from baseline to 52 weeks, measured with accelerometrics
- Changes in VO2-peak from baseline to 52 weeks, measured by the standardised walking test (in the InterWalk)
- Change in Endurance in the lower extremities from baseline to 52 weeks, measured by sit-to-stand (30 seconds)
- (and 4 more...)
|
513 |
All |
18 Years and older (Adult, Senior) |
NCT02341690 |
INTERWALK |
|
January 2015 |
January 2018 |
January 2018 |
January 19, 2015 |
March 29, 2017 |
|
- University of Copenhagen
Copenhagen, Denmark
|
| 30 |
NCT00734474 |
Completed
Has Results |
A Study of LY2189265 Compared to Sitagliptin in Participants With Type 2 Diabetes Mellitus on Metformin |
- Diabetes Mellitus, Type 2
|
- Drug: LY2189265
- Drug: Sitagliptin
- Drug: Placebo solution
- (and 2 more...)
|
Interventional |
Phase 2
Phase 3 |
- Eli Lilly and Company
- United BioSource Corporation
- Tessella Inc.
- Berry Consultants
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Glycosylated Hemoglobin (HbA1c) Change From Baseline
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at the Dose Decision Point
- Durability of Change From Baseline in Glycosylated Hemoglobin (HbA1c)
- (and 27 more...)
|
1202 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00734474 |
11422
H9X-MC-GBCF
CTRI/2009/091/000969 |
|
August 2008 |
June 2011 |
July 2012 |
August 14, 2008 |
April 20, 2015 |
January 28, 2015 |
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Peoria, Arizona, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Phoenix, Arizona, United States - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tucson, Arizona, United States - (and 96 more...)
|
| 31 |
NCT03390959 |
Recruiting |
Effectiveness of Proprioceptive Training on Plantar Pressure, Balance, Posture and Gait in Individuals With Diabetes Mellitus Type 2 |
- Diabetes Mellitus, Type 2
|
- Other: Proprioceptive Training
- Other: Control Group
|
Interventional |
Not Applicable |
- Kelly Antunes e Silva Oliveira
- Universidade Federal de Pernambuco
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Plantar Pressure
- Balance
- Posture
- (and 2 more...)
|
14 |
All |
45 Years to 80 Years (Adult, Senior) |
NCT03390959 |
Proprioceptive DM2
Feedback N.2.052.913 |
|
May 10, 2017 |
March 30, 2018 |
March 30, 2018 |
January 5, 2018 |
January 5, 2018 |
|
- Maria das Graças Araujo
Recife, Pernambuco, Brazil
|
| 32 |
NCT01719640 |
Completed |
UCMSC and BMMNC in Type 2 Diabetes Mellitus |
- Diabetes Mellitus, Type 2
|
- Drug: infusion of UCMSCs
- Drug: infusion BMMNCs
- Drug: insulin
|
Interventional |
Phase 1
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- HbA1c
- exogenous insulin requirements
- fasting hemoglucose
- (and 2 more...)
|
30 |
All |
40 Years to 65 Years (Adult) |
NCT01719640 |
MSC-BMMNC-DM |
|
January 2011 |
January 2014 |
January 2017 |
November 1, 2012 |
September 21, 2017 |
|
- Fuzhou General Hospital, Xiamen Univ
Fuzhou, Fujian, China
|
| 33 |
NCT01915264 |
Withdrawn |
GLucobay M - Evaluation Of Safety and Effectiveness in Type 2 Diabetes Not Well Controlled on Monotherapy in Real Life Practice |
- Diabetes Mellitus, Type 2
|
- Drug: Acarbose/Metformin (Glucobay M, BAY81-9783)
|
Observational |
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Incidence of severe hypoglycemia or documented symptomatic or asymptomatic hypoglycemic events reported as adverse events
- Incidence of adverse events other than hypoglycemia reported
- Mean change in HbA1c level
- (and 8 more...)
|
0 |
All |
Child, Adult, Senior |
NCT01915264 |
16445
GB1310IN |
GLORY |
August 2015 |
December 2016 |
March 2017 |
August 2, 2013 |
April 25, 2016 |
|
|
| 34 |
NCT00728351 |
Completed |
Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%) |
- Diabetes Mellitus, Type 2
|
- Drug: vildagliptin + metformin
- Drug: metformin
|
Interventional |
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- HbA1c reduction after 24 weeks of treatment in patients with T2DM inadequately controlled with metformin monotherapy
- FPG reduction
- Safety and tolerability
- (and 2 more...)
|
317 |
All |
18 Years to 78 Years (Adult, Senior) |
NCT00728351 |
CLMF237A2309 |
|
June 2008 |
February 2010 |
|
August 5, 2008 |
January 4, 2013 |
|
- Pine Bluff, Arkansas, United States
- Long Beach, California, United States
- Denver, Colorado, United States
- (and 60 more...)
|
| 35 |
NCT00380445 |
Completed |
Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- To explore whether vildagliptin augments insulin mediated inhibition of adipose tissue lipid mobilization following a mixed meal in patients with type 2 diabetes
- To measure the effects of vildagliptin on tissue carbohydrate metabolism (skeletal muscle)
|
21 |
All |
30 Years to 65 Years (Adult) |
NCT00380445 |
CLAF237A2379 |
|
January 2006 |
April 2007 |
April 2007 |
September 26, 2006 |
February 23, 2017 |
|
- Novartis Pharmaceuticals
East Hanover, New Jersey, United States - Novartis Investigative Site
Investigative Centers, Germany
|
| 36 |
NCT01715649 |
Completed |
Telehealth Remote Patient Monitoring Study in People With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Behavioral: Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose
|
Interventional |
Not Applicable |
- Sutter Health
- LifeScan
- GE Healthcare
- University of California, Davis
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Hemoglobin A1c
- Empowerment
- Behavior Change
- Knowledge
|
90 |
All |
30 Years to 70 Years (Adult, Senior) |
NCT01715649 |
1208042ex |
|
November 2012 |
May 2014 |
May 2014 |
October 29, 2012 |
November 18, 2014 |
|
- Sutter Health
Sacramento, California, United States
|
| 37 |
NCT01792635 |
Terminated
Has Results |
A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus |
- Diabetes Mellitus, Type 2
|
- Drug: PF-05175157
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Glucose Infusion Rates (GIR) in Part A
- Endogenous Gucose Production (EGP) in Part A
- [6,6-2H2] Plasma Glucose Enrichment (PGE) in Part A
- (and 14 more...)
|
19 |
All |
18 Years to 65 Years (Adult) |
NCT01792635 |
B1731003 |
|
December 2012 |
May 2014 |
May 2014 |
February 15, 2013 |
February 16, 2017 |
February 16, 2017 |
- Profil Institute for Clinical Research, Inc.
Chula Vista, California, United States
|
| 38 |
NCT00256867 |
Completed
Has Results |
A Study In Patients With Type 2 Diabetes Mellitus |
- Diabetes Mellitus, Type 2
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
|
- Median Percent Change From Baseline to Week 6 in LDL-c in FDC and RSG Monotherapy
- Mean Change From Baseline to Week 16 in Glycosylated Hemoglobin A1c (HbA1c) in FDC and SIMV Monotherapy
- Median Percent Change From Baseline to Week 6 in LDL-c
- (and 10 more...)
|
369 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00256867 |
AVS101946 |
|
August 18, 2005 |
October 31, 2006 |
October 31, 2006 |
November 22, 2005 |
March 23, 2018 |
March 23, 2018 |
- GSK Investigational Site
Tucson, Arizona, United States - GSK Investigational Site
Fresno, California, United States - GSK Investigational Site
Wheat Ridge, Colorado, United States - (and 82 more...)
|
| 39 |
NCT03039569 |
Recruiting |
Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients |
- Diabetes Mellitus, Type 2
|
- Behavioral: Text messaging
|
Interventional |
Not Applicable |
- University of Nebraska Lincoln
- The Methodist Hospital System
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Diabetes Self-Care Activities Survey
- Self-report hemoglobin A1C
- patient's cardiovascular diseases awareness questionnaire
- (and 4 more...)
|
100 |
All |
30 Years and older (Adult, Senior) |
NCT03039569 |
16200 |
|
February 15, 2017 |
May 2018 |
August 2018 |
February 1, 2017 |
October 26, 2017 |
|
- University of Nebraska-Lincoln (with Methodist Hospital System)
Lincoln, Nebraska, United States
|
| 40 |
NCT02737657 |
Completed |
An Observational Study to Evaluate Tolerability of Canagliflozin and Sulphonylurea in Type 2 Diabetes Patients During Ramadan |
- Diabetes Mellitus, Type 2
|
|
Observational |
|
- Janssen-Cilag International NV
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Percentage of Participants With at Least one Episode of Hypoglycaemia
- Number of Participants With Volume Depletion Events
- Treatment Adherence Based on the Percentage of Prescribed Doses of Canagliflozin or Sulphonylurea Taken by Participants
- (and 9 more...)
|
379 |
All |
18 Years to 65 Years (Adult) |
NCT02737657 |
CR108100
28431754DIA4016 |
CRATOS |
April 2016 |
September 2016 |
September 2016 |
April 14, 2016 |
November 15, 2016 |
|
- Kuwait City, Kuwait
- Amioun, Lebanon
- Beirut, Lebanon
- (and 6 more...)
|
| 41 |
NCT00790660 |
Completed |
A Study to Assess the Safety and Tolerability of ASP1941 in Adults With Type 2 Diabetes Mellitus. |
- Diabetes Mellitus, Type 2
|
- Drug: ASP1941
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Evaluation of safety through clinical safety labs and adverse events
- Evaluation of routine PK and PD parameters
|
61 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT00790660 |
1941-CL-0016 |
|
October 23, 2008 |
March 6, 2009 |
March 6, 2009 |
November 13, 2008 |
April 2, 2018 |
|
- San Antonio, Texas, United States
|
| 42 |
NCT02542722 |
Completed |
Type 2 Diabetes Prevention |
- Diabetes Mellitus, Type 2
|
- Behavioral: Control
- Behavioral: Intensive Intervention
|
Interventional |
Not Applicable |
- Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
- Hospital Regional Universitario de Málaga
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Incidence of type 2 diabetes in subjects at risk
|
390 |
All |
40 Years to 65 Years (Adult) |
NCT02542722 |
P09-CTS-5125
PI081592 |
PIZARRA |
January 2009 |
January 2014 |
January 2015 |
September 7, 2015 |
September 9, 2015 |
|
|
| 43 |
NCT00329225 |
Completed |
Rosiglitazone In Subjects With Type 2 Diabetes Mellitus Who Are Inadequately Controlled On Insulin |
- Diabetes Mellitus, Type 2
|
|
Interventional |
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- HbA1c at each visit
- FPG at each visit C-peptide at each visit lipids at each visit BNP at each visit CRP at each visit PAI-1 at each visit MMP-9 at each visit
|
630 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT00329225 |
49653/347 |
|
September 2002 |
April 2004 |
April 2004 |
May 24, 2006 |
September 15, 2016 |
|
- GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Birmingham, Alabama, United States - GSK Investigational Site
Fairfield, Alabama, United States - (and 128 more...)
|
| 44 |
NCT00380380 |
Completed |
A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes. |
- Diabetes Mellitus, Type 2
|
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Single
- Primary Purpose: Treatment
|
- Evaluate the effects of acute effects of vildagliptin on gastric emptying
- Effect on steady state levels of active GLP-1 and GIP
- Change in fasting and postprandial glucose levels.
- (and 4 more...)
|
18 |
All |
30 Years to 65 Years (Adult) |
NCT00380380 |
CLAF237A2378 |
|
January 2006 |
November 2006 |
November 2006 |
September 26, 2006 |
February 23, 2017 |
|
- Munich, 81377, Germany
Munich, Germany
|
| 45 |
NCT02910141 |
Completed |
Individual Patient Data Meta-analysis of CSII vs. MDI in Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Device: Continuous subcutaneous insulin infusion
|
Observational |
|
- King's College London
- University of Leicester
- University Hospital, Caen
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- HbA1c
- Insulin dose
- Weight or BMI
|
590 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT02910141 |
IPDMetaT2 |
|
January 2014 |
January 2016 |
December 2016 |
September 21, 2016 |
March 3, 2017 |
|
|
| 46 |
NCT02229240 |
Withdrawn |
Albiglutide Versus Placebo Added-on to Basal-Bolus Insulin Therapy in Subjects With Type 2 Diabetes Mellitus |
- Diabetes Mellitus, Type 2
|
- Drug: Albiglutide
- Drug: Matching albiglutide placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percentage of subjects with severe or documented symptomatic hypoglycemia through Week 26
- Change from baseline in glycosylated hemoglobin (HbA1c) at Week 26
- Change from baseline in body weight at Week 26 and over time
- (and 10 more...)
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT02229240 |
111892 |
|
August 2015 |
December 2015 |
December 2015 |
September 1, 2014 |
January 11, 2016 |
|
|
| 47 |
NCT01809327 |
Completed
Has Results |
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control With Diet and Exercise |
- Diabetes Mellitus, Type 2
|
- Drug: Canagliflozin 100 mg
- Drug: Canagliflozin 300 mg
- Drug: Metformin XR
|
Interventional |
Phase 3 |
- Janssen Research & Development, LLC
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Glycated Hemoglobin (HbA1c) From Baseline at Week 26
- Percent Change in Body Weight From Baseline to Week 26
- Percentage of Participants With Glycated Hemoglobin (HbAIc) Less Than 7 Percent at Week 26
- (and 4 more...)
|
1186 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01809327 |
CR100034
28431754DIA3011
2011-000400-17 |
|
June 4, 2013 |
December 2, 2014 |
December 2, 2014 |
March 12, 2013 |
July 11, 2017 |
January 6, 2016 |
- Birmingham, Alabama, United States
- Phoenix, Arizona, United States
- Encinitas, California, United States
- (and 134 more...)
|
| 48 |
NCT01055808 |
Completed |
Observational Study in Japanese Type 2 Diabetes Patients |
- Diabetes Mellitus, Type 2
|
|
Observational |
|
|
Industry |
- Time Perspective: Prospective
|
- Changes in Health Related Quality of Life (ITR-QOL) in insulin treated type 2 diabetes at baseline and 12 weeks after a significant change in insulin treatment regimen
- Summarize by occurrence the reason for insulin treatment change at study entry
- Change in HbA1c at baseline and 12 weeks after a significant change in insulin treatment regimen
- (and 5 more...)
|
677 |
All |
20 Years and older (Adult, Senior) |
NCT01055808 |
13614
F3Z-JE-PV06 |
INSIGHTS |
January 2010 |
November 2010 |
November 2010 |
January 26, 2010 |
December 10, 2010 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Hyogo, Japan
|
| 49 |
NCT01902316 |
Completed |
Clinical Verification of Peptide Biomarkers for Type 2 Diabetes Mellitus |
- Diabetes Mellitus, Type 2
|
|
Observational |
|
- Beijing Institute of Technology
|
Other |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- measurement of the amount of plasma peptides
|
389 |
All |
35 Years to 72 Years (Adult, Senior) |
NCT01902316 |
deng01 |
|
January 2009 |
December 2011 |
December 2011 |
July 18, 2013 |
July 18, 2013 |
|
|
| 50 |
NCT01338870 |
Completed
Has Results |
Study of Safety and Efficacy of PF-04991532 in Subjects With Type 2 Diabetes |
- Diabetes Mellitus, Type 2
|
- Drug: Placebo
- Drug: 25 mg PF-04991532
- Drug: 75 mg PF-04991532
- (and 3 more...)
|
Interventional |
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
- Change From Baseline in Fasting Plasma Glucose at Week 1, 2, 4, 8 and 12
- Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 1, 2, 4 and 8
- (and 4 more...)
|
301 |
All |
18 Years to 70 Years (Adult, Senior) |
NCT01338870 |
B2611003 |
|
June 2011 |
March 2012 |
March 2012 |
April 20, 2011 |
April 23, 2013 |
April 23, 2013 |
- Pfizer Investigational Site
Little Rock, Arkansas, United States - Pfizer Investigational Site
Roseville, California, United States - Pfizer Investigational Site
Denver, Colorado, United States - (and 39 more...)
|
Create an RSS feed from your search for:
Download the search results for: